Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

NCT03397914 Phase 4 COMPLETED

Prospective randomized study comparing different colistin dosing regimens in paediatric cancer patient with MDR gram-negative infection or sepsis

Details

Lead sponsor	National Cancer Institute, Egypt
Phase	Phase 4
Status	COMPLETED
Enrolment	70
Start date	2017-01
Completion	2019-03

Conditions

• Gram-Negative Bacterial Infections
• Pediatric Cancer
• Colistin
• Colistin Adverse Reaction
• MIC

Interventions

• Colistimethate Sodium

Primary outcomes

• clinical improvement, — 7- 14 days
  time to defervescence

Countries

Egypt